相关实验视频
Updated: Sep 12, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.6K
基因饮食作为帕金森病治疗的混合方法可行性研究
Kate Worster1, Dana Colgan1,2, Alexandra Vita1,3
1Helfgott Research Institute, National University of Natural Medicine, Portland, OR, United States.
Frontiers in nutrition
|August 7, 2025
概括
对帕金森病 (PD) 患者来说,低乳制品的修改基因饮食 (KD) 是可行的和可以接受的. 这种方法可以提供与传统KDs相似的好处,同时减轻与乳制品相关的症状恶化.
科学领域:
- 神经学 神经学
- 营养科学 营养科学
- 饮食干预 饮食干预
背景情况:
- 帕金森病 (PD) 患者可能受益于性饮食 (KD).
- 在传统的KD中,高乳制品摄入量可能会使PD症状恶化.
- 修改后的低乳制品KD为PD管理提供了潜在的替代方案.
研究的目的:
- 评估一种新的,低乳制品KD在PD患者中的可行性和可接受性.
- 评估这种修改后的KD对生活质量和功能运动的影响.
- 为了探索对帕金森病的乳制品限制的基因方法.
主要方法:
- 十二名PD患者坚持12周的低乳制品KD与营养支持.
- 每日的食物日记跟踪了宏观营养素的摄入量,以确保坚持和确认症.
- 定期评估包括血液,尿液,生命体,体重,生活质量 (PDQ-39) 和功能运动测试 (UPDRS,迷你BEST等). ) 的情况.
主要成果:
- 通过平均巨量营养素摄入量和升高的β-基酸盐水平证实了营养症.
- 在UPDRS得分,迷你BEST,步态结和生活质量方面观察到显著的临床改善.
- 参与者经历了体重减轻,在便秘方面报告的变化很小.
结论:
- 对于帕金森病患者来说,修改后的低乳制品KD是可行的和可以接受的.
- 这种饮食方法可以提供与传统KDs相比的治疗益处.
- 减少KD患者的乳制品摄入量可以减轻PD患者的潜在不良影响.
相关概念视频
Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
Parkinson's Disease: Overview
708
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
708

